semaglutide heart failure reduced ejection fraction And Clinical Outcomes In Patients With With And Obesity: A Retrospective Cohort Study Using Real World Data www.x.com/AmbrizMau REFERENCIA: Krüger N, et

Salcaprozate sodium (SNAC), an absorption enhancer in the oral tablet, has been shown to cross the placenta and reach fetal tissues in rats

Of the 14 semaglutide-treated patients that developed anti-semaglutide antibodies, 7 patients (0.2% of the overall population) developed antibodies cross-reacting with native GLP-1

It is your body recalibrating to a new baseline

Regular follow-ups with healthcare providers ensure that adjustments can be made to the treatment regimen as needed, optimizing long-term outcomes, and helping patients maintain a healthier weight for years improving quality of life as well as health outcomes